ESTRO 2024 - Abstract Book

S2182

Clinical - Upper GI

ESTRO 2024

The analysis encompassed 125 LAPC patients, with a median follow-up period of 17 months (range: 3-92 months). The median OS was 23 months, with a 2-year OS rate of 40.8%. Median LC was not reached, and the 2-year LC rate was 60.1%. Univariate analysis (see Table 1) indicated that patients with cT4 (p<0.001), tumor diameter > 3.7 cm (p=0.038), those treated with total doses ≥ 30.0 Gy (p=0.012), and those receiving modern CHT regimens such as FOLFIRINOX (p=0.014) had statistically significant improvements in LC. Patients with ECOG-PS=0 (p=0.004), those who received neoadjuvant CHT (p<0.001), and especially those treated with gemcitabine+Nab-paclitaxel (p=0.042), experienced enhanced OS. In multivariable analysis, tumor diameter >3.7 cm was confirmed as a significant predictor of improved LC (HR: 0.42, 95% CI 0.19-0.93, p=0.034) and improved OS (HR: 0.48, 95% CI 0.25-0.90, p=0.022). Additionally, cT4 tumor stage (HR: 0.34, 95% CI 0.15-0.77, p=0.010) and novel CHT regimens such as gemcitabine+Nab-paclitaxel or FOLFIRINOX (HR: 0.34, 95% CI 0.15-0.77, p=0.010) emerged as independent predictors of improved OS.

Conclusion:

The combination of SBRT and contemporary CHT regimens has demonstrated its effectiveness in managing LAPC, leading to a significant improvement in OS. Our analysis validates previous observations regarding the correlation between larger tumor size and cT4 LAPC with prolonged OS. Future investigations are warranted to elucidate the underlying factors contributing to these intriguing findings.

Keywords: SBRT, pancreatic cancer

1024

Digital Poster

Predictive factors of liver toxicity after SBRT of primary liver tumors

Carolina De la Pinta 1,2 , David Sevillano 1 , Juan David García 1 , Margarita Martín 1 , Desiree Valencia 1 , Esther Montero 1 , Abel Sacristán 1 , Sara Barrio 1 , Sonsoles Sancho 1 1 Ramon y Cajal Hospital, Radiation Oncology, Madrid, Spain. 2 IRYCIS, Biomarkers and therapeutic targets group, Madrid, Spain

Purpose/Objective:

Stereotactic body radiation therapy (SBRT) is an effective therapeutic alternative in primary liver tumors. Prediction of radioinduced liver toxicity could prevent worsening of liver function and personalization of treatments to patient characteristics. Therefore, we evaluated the clinical factors predictive of liver toxicity in patients with liver tumors undergoing SBRT in our institution.

Material/Methods: